Your browser doesn't support javascript.
loading
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial.
Motzer, Robert J; Escudier, Bernard; George, Saby; Hammers, Hans J; Srinivas, Sandhya; Tykodi, Scott S; Sosman, Jeffrey A; Plimack, Elizabeth R; Procopio, Giuseppe; McDermott, David F; Castellano, Daniel; Choueiri, Toni K; Donskov, Frede; Gurney, Howard; Oudard, Stéphane; Richardet, Martin; Peltola, Katriina; Alva, Ajjai S; Carducci, Michael; Wagstaff, John; Chevreau, Christine; Fukasawa, Satoshi; Tomita, Yoshihiko; Gauler, Thomas C; Kollmannsberger, Christian K; Schutz, Fabio A; Larkin, James; Cella, David; McHenry, M Brent; Saggi, Shruti Shally; Tannir, Nizar M.
Affiliation
  • Motzer RJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Escudier B; Department of Medical Oncology, Gustave Roussy, Villejuif, France.
  • George S; Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York.
  • Hammers HJ; Division of Hematology and Oncology, UT Southwestern Kidney Cancer Program, Dallas, Texas.
  • Srinivas S; Stanford Cancer Institute, Stanford University Medical Center, Stanford, California.
  • Tykodi SS; Department of Medicine, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Sosman JA; Department of Hematology/Oncology, Northwestern University Medical Center, Chicago, Illinois.
  • Plimack ER; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Procopio G; Fondazione Istituto Nazionale Tumori, Milan, Italy.
  • McDermott DF; Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Boston, Massachusetts.
  • Castellano D; Oncologia Medica, Hospital Universitario 12 De Octubre, Madrid, Spain.
  • Choueiri TK; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Donskov F; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.
  • Gurney H; Department of Medical Oncology, Westmead Hospital and Macquarie University, Westmead, New South Wales, Australia.
  • Oudard S; Service de Cancérologie Médicale, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France.
  • Richardet M; Fundacion Richardet Longo, Instituto Oncologico de Cordoba, Cordoba, Argentina.
  • Peltola K; Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland.
  • Alva AS; Division of Hematology and Oncology, University of Michigan, Ann Arbor, Michigan.
  • Carducci M; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, Baltimore, Maryland.
  • Wagstaff J; South West Wales Cancer Institute and Swansea University College of Medicine, Swansea, United Kingdom.
  • Chevreau C; Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France.
  • Fukasawa S; Prostate Center and Division of Urology, Chiba Cancer Center, Chiba, Japan.
  • Tomita Y; Department of Urology, Department of Molecular Oncology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
  • Gauler TC; Department of Medicine, University Hospital Essen, University of Duisburg-Essen, Duisburg, Germany.
  • Kollmannsberger CK; Division of Medical Oncology, BC Cancer-Vancouver Cancer Centre, Vancouver, British Columbia, Canada.
  • Schutz FA; Beneficencia Portuguesa de São Paulo, São Paulo, Brazil.
  • Larkin J; Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom.
  • Cella D; Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
  • McHenry MB; Department of Biostatistics, Bristol Myers Squibb, Princeton, New Jersey.
  • Saggi SS; Department of Clinical Trials, Bristol Myers Squibb, Princeton, New Jersey.
  • Tannir NM; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Cancer ; 126(18): 4156-4167, 2020 09 15.
Article in En | MEDLINE | ID: mdl-32673417
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Antineoplastic Combined Chemotherapy Protocols / Everolimus / Nivolumab / Kidney Neoplasms Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Female / Humans / Male Language: En Journal: Cancer Year: 2020 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Antineoplastic Combined Chemotherapy Protocols / Everolimus / Nivolumab / Kidney Neoplasms Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Female / Humans / Male Language: En Journal: Cancer Year: 2020 Type: Article